IBDEI1Z8 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33543,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,33543,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,33543,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,33544,0)
 ;;=E13.9^^131^1672^22
 ;;^UTILITY(U,$J,358.3,33544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33544,1,3,0)
 ;;=3^Diabetes Mellitus (Secondary) w/o Complications NEC
 ;;^UTILITY(U,$J,358.3,33544,1,4,0)
 ;;=4^E13.9
 ;;^UTILITY(U,$J,358.3,33544,2)
 ;;=^5002704
 ;;^UTILITY(U,$J,358.3,33545,0)
 ;;=E16.2^^131^1672^29
 ;;^UTILITY(U,$J,358.3,33545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33545,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,33545,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,33545,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,33546,0)
 ;;=E20.0^^131^1672^34
 ;;^UTILITY(U,$J,358.3,33546,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33546,1,3,0)
 ;;=3^Idiopathic Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,33546,1,4,0)
 ;;=4^E20.0
 ;;^UTILITY(U,$J,358.3,33546,2)
 ;;=^5002712
 ;;^UTILITY(U,$J,358.3,33547,0)
 ;;=E20.9^^131^1672^30
 ;;^UTILITY(U,$J,358.3,33547,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33547,1,3,0)
 ;;=3^Hypoparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,33547,1,4,0)
 ;;=4^E20.9
 ;;^UTILITY(U,$J,358.3,33547,2)
 ;;=^5002714
 ;;^UTILITY(U,$J,358.3,33548,0)
 ;;=E23.0^^131^1672^31
 ;;^UTILITY(U,$J,358.3,33548,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33548,1,3,0)
 ;;=3^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,33548,1,4,0)
 ;;=4^E23.0
 ;;^UTILITY(U,$J,358.3,33548,2)
 ;;=^60685
 ;;^UTILITY(U,$J,358.3,33549,0)
 ;;=E27.1^^131^1672^51
 ;;^UTILITY(U,$J,358.3,33549,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33549,1,3,0)
 ;;=3^Primary Adrenocortical Insufficiency
 ;;^UTILITY(U,$J,358.3,33549,1,4,0)
 ;;=4^E27.1
 ;;^UTILITY(U,$J,358.3,33549,2)
 ;;=^5002740
 ;;^UTILITY(U,$J,358.3,33550,0)
 ;;=E27.2^^131^1672^1
 ;;^UTILITY(U,$J,358.3,33550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33550,1,3,0)
 ;;=3^Addisonian Crisis
 ;;^UTILITY(U,$J,358.3,33550,1,4,0)
 ;;=4^E27.2
 ;;^UTILITY(U,$J,358.3,33550,2)
 ;;=^263725
 ;;^UTILITY(U,$J,358.3,33551,0)
 ;;=E27.3^^131^1672^23
 ;;^UTILITY(U,$J,358.3,33551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33551,1,3,0)
 ;;=3^Drug-induced Adrenocortical Insufficiency
 ;;^UTILITY(U,$J,358.3,33551,1,4,0)
 ;;=4^E27.3
 ;;^UTILITY(U,$J,358.3,33551,2)
 ;;=^5002741
 ;;^UTILITY(U,$J,358.3,33552,0)
 ;;=E29.1^^131^1672^52
 ;;^UTILITY(U,$J,358.3,33552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33552,1,3,0)
 ;;=3^Testicular Hypofunction
 ;;^UTILITY(U,$J,358.3,33552,1,4,0)
 ;;=4^E29.1
 ;;^UTILITY(U,$J,358.3,33552,2)
 ;;=^5002754
 ;;^UTILITY(U,$J,358.3,33553,0)
 ;;=E55.9^^131^1672^59
 ;;^UTILITY(U,$J,358.3,33553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33553,1,3,0)
 ;;=3^Vitamin D Deficiency,Unspec
 ;;^UTILITY(U,$J,358.3,33553,1,4,0)
 ;;=4^E55.9
 ;;^UTILITY(U,$J,358.3,33553,2)
 ;;=^5002799
 ;;^UTILITY(U,$J,358.3,33554,0)
 ;;=E66.01^^131^1672^38
 ;;^UTILITY(U,$J,358.3,33554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33554,1,3,0)
 ;;=3^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,33554,1,4,0)
 ;;=4^E66.01
 ;;^UTILITY(U,$J,358.3,33554,2)
 ;;=^5002826
 ;;^UTILITY(U,$J,358.3,33555,0)
 ;;=E66.8^^131^1672^42
 ;;^UTILITY(U,$J,358.3,33555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33555,1,3,0)
 ;;=3^Obesity NEC
 ;;^UTILITY(U,$J,358.3,33555,1,4,0)
 ;;=4^E66.8
 ;;^UTILITY(U,$J,358.3,33555,2)
 ;;=^5002831
 ;;^UTILITY(U,$J,358.3,33556,0)
 ;;=E66.9^^131^1672^43
 ;;^UTILITY(U,$J,358.3,33556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33556,1,3,0)
 ;;=3^Obesity,Unspec
